US FDA accepts lurasidone filing for schizophrenia
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for standard review Dainippon Sumitomo Pharma's (DSP) NDA for the atypical antipsychotic lurasidone, for the treatment of acute schizophrenia.